| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/06/2000 | WO2000038657A1 Method for preparing an effervescent granulate comprising iron gluconate, granulate thus obtained and tablets containing the same |
| 07/06/2000 | WO2000038656A1 Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient |
| 07/06/2000 | WO2000038655A1 Dosage forms comprising porous particles |
| 07/06/2000 | WO2000038653A1 Improved formulation for topical non-invasive application in vivo |
| 07/06/2000 | WO2000038649A1 Pharmaceutical composition for oral administration designed to prevent misuse at the expense of a third party |
| 07/06/2000 | WO2000038647A1 Skin protection agents containing a fragment mixture produced from hyaluronic acid by hydrolysis |
| 07/06/2000 | WO2000038646A1 Dermatological compositions containing tannic acid and a microbial proliferation inhibitor |
| 07/06/2000 | WO2000038644A1 Stable solution of zinc ions and bicarbonate and/or carbonate ions |
| 07/06/2000 | WO2000038643A1 Oral hygiene product containing spherical microparticles on the basis of linear water-insoluble polyglucans |
| 07/06/2000 | WO2000038626A2 Substrate composition and method of use for sequestration of skin irritants |
| 07/06/2000 | WO2000038625A2 Facial tissue composition and method of use for sequestration of nasal secretion skin irritants |
| 07/06/2000 | WO2000038623A1 Cosmetic or medical preparation for topical use |
| 07/06/2000 | WO2000038620A2 A composition useful to treat periodontal disease |
| 07/06/2000 | WO2000038618A2 SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
| 07/06/2000 | WO2000038537A1 α-AMYLASE-RESISTANT STARCH FOR PRODUCING FOODSTUFF AND MEDICAMENTS |
| 07/06/2000 | WO2000038536A2 Inhibitors of the bitter taste response |
| 07/06/2000 | WO2000038519A1 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy |
| 07/06/2000 | WO2000038518A1 Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors |
| 07/06/2000 | WO2000027403B1 Method for treating a patient with neoplasia by treatment with a pyrimidine analog |
| 07/06/2000 | WO2000023058A3 Use of an antianaerobic-bacterial or/and antiprotozoal agent (preferably metronidazole) in the manufacture of a medicament for the treatment of haemorrhoids |
| 07/06/2000 | WO2000021910A3 1,2-disubstituted cyclopropanes |
| 07/06/2000 | WO2000021512A3 Composition and method for treating allergic diseases |
| 07/06/2000 | WO2000020024A3 Methods for the treatment of non-thyroid disorders |
| 07/06/2000 | WO2000020023A3 Null igf for the treatment of cancer |
| 07/06/2000 | WO2000018954A3 Use of pex in the treatment of metabolic bone diseases |
| 07/06/2000 | WO2000018419A3 Methods for administration of antibiotics |
| 07/06/2000 | WO2000018417A3 Treatment of hepatitis b infection with thymosin alpha 1 and lamivudine |
| 07/06/2000 | WO2000018387A3 Antibiotic compositions for treatment of the eye, ear and nose |
| 07/06/2000 | WO2000018383A3 Antiviral combinations comprising (s)-2- ethyl-7- fluoro-3- oxo-3,4- dihydro-2h- quinoxaline-1- carboxylic acid isopropyl ester |
| 07/06/2000 | WO2000018353A3 A novel inhibitor of cataract formation |
| 07/06/2000 | WO2000018352A3 A method for treating inflammatory diseases by administering a thrombin inhibitor |
| 07/06/2000 | WO2000015201A3 Compositions comprising one or more phytosterols, phytostanols or mixtures of both and one or more alpha, beta, delta, or gamma tocotrienols or derivatives thereof and use of the compositions in treating or preventing cardiovascular disease, its underlying conditions and other disorders |
| 07/06/2000 | WO2000013686A3 Sustained release ranolazine formulations |
| 07/06/2000 | WO2000012509A3 Collections of compounds |
| 07/06/2000 | WO2000010574A9 The use of loop diuretics for hiv infection |
| 07/06/2000 | WO2000009102A3 Carboxylic acids and isosteres of n-heterocyclic compounds for vision and memory disorders |
| 07/06/2000 | WO2000008021A3 Process for preparing n,n,6- trimethyl-2 -(4-methylphenyl)- imidazo-[1,2-a] -pyridine-3- acetamide and salts thereof |
| 07/06/2000 | WO1999064035A9 β2-ADRENERGIC RECEPTOR AGONISTS |
| 07/06/2000 | WO1999064012A8 Altering sex ratio of offspring in mammals |
| 07/06/2000 | WO1999063115A9 Use of cathepsin s in the diagnosis and treatment of endometriosis |
| 07/06/2000 | WO1999061600A9 A method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upf1p, eucaryotic release factor 1 and eucaryotic release factor 3 |
| 07/06/2000 | WO1999052514A3 Pharmaceutical composition and combination preparation for immunosuppressive therapy |
| 07/06/2000 | DE19900054A1 Taxane enthaltende stabile und sterile Emulsion und Verfahren zu ihrer Herstellung Taxanes containing sterile and stable emulsion and process for their preparation |
| 07/06/2000 | DE19860699A1 Well tolerated oral antidiabetic agent composition, contains conventional active agent, e.g. glibenclamide, and silicone compound to eliminate need for induction period during therapy |
| 07/06/2000 | DE19860698A1 Neue pharmazeutische Zusammensetzung New pharmaceutical composition |
| 07/06/2000 | DE19860375A1 Alpha Amylase-resistente Stärke zur Herstellung von Nahrungs- und Arzneimittel Alpha amylase-resistant starch for the production of food and drugs |
| 07/06/2000 | DE19860373A1 Mundpflegemittel enthaltend shärische Mikropartikel auf Basis linearer wasserunlöslicher Polyglucane Oral care compositions comprising shärische microparticles based on linear water-insoluble polyglucans |
| 07/06/2000 | DE19859426A1 Verwendung von phosphororganischen Verbindungen zur therapeutischen und prophylaktischen Behandlung von Infektionen Use of organophosphorus compounds for therapeutic and prophylactic treatment of infections |
| 07/06/2000 | CA2362492A1 Phenethyl-5-bromopyridylthiourea (pbt) and dihydroalkoxybenzyloxopyrimidine (dabo) derivatives exhibiting spermicidal activity |
| 07/06/2000 | CA2361149A1 Aromatic amides |
| 07/06/2000 | CA2358687A1 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
| 07/06/2000 | CA2358315A1 Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
| 07/06/2000 | CA2358095A1 Heteroroaromatic amides as inhibitor of factor xa |
| 07/06/2000 | CA2358094A1 Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 |
| 07/06/2000 | CA2358091A1 Antithrombotic amides |
| 07/06/2000 | CA2358067A1 (2-imidazolin-2-ylamino) quinoxaline derivatives for the treatment of pain |
| 07/06/2000 | CA2358047A1 Substituted (aminoiminomethyl or aminomethyl)benzoheteroaryl compounds |
| 07/06/2000 | CA2357977A1 Method for prevention or treatment of acute allograft rejection and a pharmaceutical composition therefor |
| 07/06/2000 | CA2357837A1 The utilisation of inhibitors of the sodium hydrogen exchanger for producing a medicament for preventing organ dysfunctions and diseases related to a particular age and for prolonging life |
| 07/06/2000 | CA2357765A1 Liposomic niflumic acid - new transdermal anti-inflammatory medicine |
| 07/06/2000 | CA2357042A1 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy |
| 07/06/2000 | CA2356986A1 Compounds and methods for modulation of estrogen receptors |
| 07/06/2000 | CA2356929A1 Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combonation therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356897A1 Apparatus and process for preparing crystalline particles |
| 07/06/2000 | CA2356895A1 Aciclovir compositions containing dimethicone |
| 07/06/2000 | CA2356838A1 Imidazole compounds and medicinal use thereof |
| 07/06/2000 | CA2356756A1 Prenyl transferase inhibitors |
| 07/06/2000 | CA2356748A1 Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356692A1 Hydrophilic ampholytic polymer |
| 07/06/2000 | CA2356671A1 Protease inhibitors |
| 07/06/2000 | CA2356664A1 Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications |
| 07/06/2000 | CA2356638A1 Indole and indolizidine derivatives for the treatment of migraine |
| 07/06/2000 | CA2356622A1 Compounds which affect mrna stability and uses therefor |
| 07/06/2000 | CA2356608A1 A. fumigatus acetyl coenzyme-a carboxylase genes and polypeptides abd uses thereof |
| 07/06/2000 | CA2356607A1 Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications |
| 07/06/2000 | CA2356606A1 Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356551A1 Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors |
| 07/06/2000 | CA2356548A1 Human brainiac-5 |
| 07/06/2000 | CA2356547A1 Combination therapy of radiation and a cox-2 inhibitor for the treatment of neoplasia |
| 07/06/2000 | CA2356542A1 Peptidoglycan recognition proteins |
| 07/06/2000 | CA2356515A1 Combinations for cardiovascular indications |
| 07/06/2000 | CA2356462A1 Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356459A1 Method of using a matrix metalloproteinase inhibitor and radiation therapy as combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356453A1 Anti-hiv infection agents and method for treating hiv infection |
| 07/06/2000 | CA2356402A1 Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia |
| 07/06/2000 | CA2356399A1 Anthraquinone anticancer drugs |
| 07/06/2000 | CA2356382A1 Agent for treating visual cell function disorder |
| 07/06/2000 | CA2356319A1 Thyroid receptor ligands |
| 07/06/2000 | CA2356302A1 Method of using a cyclooxygenase-2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356269A1 Pain control agent |
| 07/06/2000 | CA2356262A1 Use of bisphosphonates for the prevention and treatment of infectious processes |
| 07/06/2000 | CA2356214A1 Heterocyclic amides as inhibitors of factor xa |
| 07/06/2000 | CA2356156A1 Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications |
| 07/06/2000 | CA2356057A1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 07/06/2000 | CA2355891A1 Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient |
| 07/06/2000 | CA2355872A1 Method for preparing an effervescent granulate comprising iron gluconate, granulate thus obtained and tablets containing the same |
| 07/06/2000 | CA2355744A1 Novel inhibitors of farnesyl-protein transferase |
| 07/06/2000 | CA2355281A1 Thrombin inhibitors |
| 07/06/2000 | CA2355254A1 Use of peptide |
| 07/06/2000 | CA2355097A1 Inositol-containing hexasaccharides, their synthesis and their uses |